Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-08-30
2004-12-07
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S125000, C544S361000, C546S061000, C546S062000, C546S070000, C514S253030, C514S254080, C514S284000, C514S285000
Reexamination Certificate
active
06828319
ABSTRACT:
1. FIELD OF THE INVENTION
The invention relates to indeno[1,2-c]isoquinoline compounds; compositions comprising an indeno[1,2-c]isoquinoline compound; and methods for treating or preventing an inflammatory disease or a reperfusion disease.
2. BACKGROUND OF THE INVENTION
Inflammatory diseases, such as arthritis, colitis, and autoimmune diabetes, typically manifest themselves as disorders distinct from those associated with reperfusion diseases, e.g., stroke and heart attack, and can clinically manifest themselves as different entities. However, there can be common underlying mechanisms between these two types of disorders. In particular, inflammatory disease and reperfusion disease can induce proinflammatory cytokine and chemokine synthesis which can, in turn, result in production of cytotoxic free radicals such as nitric oxide and superoxide. NO and superoxide can react to form peroxynitrite (ONOO
−
) (Szabó et al., Shock 6:79-88, 1996).
The ONOO
−
-induced cell necrosis observed in inflammatory disease and in reperfusion disease involves the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS). Activation of PARS is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion disease (Szabó et al., Trends Pharmacol. Sci. 19: 287-98, 1998).
A number of PARS inhibitors have been described in the art. See, e.g., Banasik et al., J. Biol. Chem., 267:1569-75, 1992, and Banasik et al., Mol. Cell. Biochem., 138:185-97, 1994; WO 00/39104; WO 00/39070; WO 99/59975; WO 99/59973; WO 99/11649; WO 99/11645; WO 99/11644; WO 99/11628; WO 99/11623; WO 99/11311; WO 00/42040; Zhang et al., Biochem. Biophys. Res. Commun., 278:590-98,2000; White et al., J. Med. Chem., 43 :4084-4097, 2000; Griffin et al., J. Med. Chem., 41:5247-5256, 1998; Shinkwin et al., Bioorg. Med. Chem., 7:297-308, 1999; and Soriano et al., Nature Medicine, 7:108-113, 2001. Adverse effects associated with administration of PARS inhibitors have been discussed in Milan et al, Science, 223:589-591, 1984.
Indeno[1,2-c]isoquinoline derivatives have been previously discussed in the art. For example, cytotoxic non-camptothecin topoisomerase I inhibitors are reported in Cushman et al., J. Med. Chem., 43:3688-3698, 2000 and Cushman et al., J. Med. Chem. 42:446-57, 1999; indeno[1,2-c]isoquinolines are reported as antineoplastic agents in Cushman et al., WO 00/21537; and as neoplasm inhibitors in Hrbata et al., WO 93/05023.
Syntheses of indeno[1,2-c]isoquinoline derivatives have been reported. For example, see Wawzonek et al., Org. Prep. Proc. Int. 14:163-8, 1982; Wawzonek et al., Can. J. Chem. 59:2833, 1981; Andoi et al, Bull. Chem. Soc. Japan, 47:1014-17, 1974; Dusemund et al., Arch. Pharm (Weinheim, Ger.), 3 17:381-2, 1984; and Lal et al., Indian J. Chem., Sect. B, 38B:33-39, 1999.
There remains, however, a need in the art for compounds useful for treating or preventing inflammatory diseases or reperfusion diseases.
Citation of any reference in Section 2 of this application is not an admission that the reference is prior art.
3. SUMMARY OF THE INVENTION
The invention is based in part on the discovery of novel substituted tetracyclic benzamide derivatives and their demonstrated effects in the treatment of inflammation, cell death and in treating shock and reperfusion diseases.
Accordingly, in one aspect the invention includes a compound of Formula I, Formula Ia, Formula Ib, Formula II or Formula III, or a pharmaceutically acceptable salt or hydrate thereof (an “Indeno[1,2-c]isoquinoline Compound”) as set forth below in the detailed description of the invention.
Also provided by the invention is a method for treating or preventing an inflammatory disease or a reperfusion diseasein a subject, comprising administering to a subject in need of such treatment or prevention an effective amount of an Indeno[1,2-c]isoquinoline Compound.
In a further aspect, the invention also includes a method for making an Indeno[1,2-c]isoquinoline Compound.
The Indeno[1,2-c]isoquinoline Compounds can be used to treat or prevent a variety of conditions and diseases, including, but not limited to, an inflammatory disease or a reperfusion disease.
The invention also includes pharmaceutical compositions that comprise an effective amount of an Indono[1,2-c]isoquinoline Compound and a pharmaceutically acceptable carrier. The compositions are useful for treating or preventing an inflammatory disease or a reperfusion disease. The invention includes an Indeno[1,2-c]isoquinoline Compound when provided as a pharmaceutically acceptable prodrug, a hydrated salt, such as a pharmaceutically acceptable salt, or mixtures thereof.
The details of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, illustrative methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 5079246 (1992-01-01), Forbes et al.
patent: 5260316 (1993-11-01), Van Duzer et al.
patent: 5262564 (1993-11-01), Kun et al.
patent: 5597831 (1997-01-01), Michalsky, deceased et al.
patent: 6346535 (2002-02-01), Cotter et al.
patent: 6346536 (2002-02-01), Li et al.
patent: 6498194 (2002-12-01), Cotter et al.
patent: 6635642 (2003-10-01), Jackson et al.
patent: 2002/0099063 (2002-07-01), Cotter et al.
patent: 2004/0039009 (2004-02-01), Jagtap et al.
patent: WO 93/05023 (1993-03-01), None
patent: WO 99/11311 (1999-03-01), None
patent: WO 99/11623 (1999-03-01), None
patent: WO 99/11628 (1999-03-01), None
patent: WO 99/11644 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/59973 (1999-11-01), None
patent: WO 99/59975 (1999-11-01), None
patent: WO 00/21537 (2000-04-01), None
patent: WO 00/39070 (2000-07-01), None
patent: WO 00/39104 (2000-07-01), None
patent: WO 00/42040 (2000-07-01), None
Yamaguchi, S. et al. : The synthesis of Benzofuroquinolines. J. Heterocyclic Chem. vol. 32, pp. 419-423, 1995.*
Hiremath, S.P. et al. : A new method of synthesis of 6h, 11H-indolo[3,2-c]-isoquinolin-5-ones/thiones and their reactions. J. Heterocyclic Chem. vol. 3O, pp. 603-609, 1993.*
Abdelkarim et al., 2001, “Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke”, Int. J. Mol. Med. 7:255-260.
Ando et al., 1974, “Cyclization reactions of 1,2-bis(2-cyanophenyl)propionitriles. II. Synthesis of 5-amino-4,7-dimethoxy-11H-indeno[1,2-c]isoquinolin-11-one”, Bull. Chem. Soc. Japan 47:1014-1017.
Banasik and Ueda, 1994, “Inhibitors and activators of ADP-ribosylation reactions”, Mol. Cell. Biol. 138:185-197.
Banasik et al., 1992, “Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl) transferase”, J. Biol. Chem. 267:1569-1575.
Cushman et al., 2000, “Synthesis of new indeno[1,2-c]isoquinolines: Cytotoxic non-camptothecin topoisomerase I inhibitors”, J. Med. Chem. 43:3688-3698.
Dusemund and Kröger, 1984, “5-hydroxyisoindolo[2,1b]isoquinolin-7-one: Synthesis and isomerization”, Arch. Pharm. (Weinheim) 317:381-382.
Griffin et al., 1998, “Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)”, J. Med. Chem. 41:5247-5256.
Grupp et al., 1999, “Protection
Baloglu Erkan
Jagtap Prakash
Salzman Andrew L.
Szabo Csaba
van Duzer John H.
Aulakh Charanjit S.
Inotek Pharmaceuticals Corporation
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Substituted indeno[1,2-c]isoquinoline derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indeno[1,2-c]isoquinoline derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indeno[1,2-c]isoquinoline derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3318565